{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T01:51:30Z","timestamp":1694829090590},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.ejim.2012.10.013","type":"journal-article","created":{"date-parts":[[2012,11,17]],"date-time":"2012-11-17T17:45:24Z","timestamp":1353174324000},"page":"100-103","source":"Crossref","is-referenced-by-count":5,"title":["How to manage HBeAg-negative chronic HBV infection with normal alanine aminotransferase levels in clinical practice?"],"prefix":"10.1016","volume":"24","author":[{"given":"Claudio","family":"Puoti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2012.10.013_bb0005","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2012.10.013_bb0010","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","article-title":"Hepatitis B, virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures","volume":"11","author":"Lavanchy","year":"2004","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.ejim.2012.10.013_bb0015","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0140-6736(82)90104-0","article-title":"Susceptibility of chronic symptomless HBsAg carriers to ethanol induced hepatic damage","volume":"2","author":"Villa","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2012.10.013_bb0020","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2012.10.013_bb0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1055\/s-2003-37590","article-title":"Natural history and prognosis of hepatitis B","volume":"23","author":"Fattovich","year":"2003","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.ejim.2012.10.013_bb0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-2004-828674","article-title":"The natural history of chronic hepatitis B virus infection","volume":"24","author":"McMahon","year":"2004","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.ejim.2012.10.013_bb0035","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: incidence and risk factors","volume":"127","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2012.10.013_bb0040","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jhep.2011.11.030","article-title":"Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review","volume":"57","author":"Papatheodoridis","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2012.10.013_bb0045","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0168-8278(02)00004-1","article-title":"Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers","volume":"36","author":"Martinot-Peignoux","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2012.10.013_bb0050","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-2893.2011.01450.x","article-title":"Serial HBV DNA levels in patients with persistently normal transaminase over 10years following spontaneous HBeAg seroconversion","volume":"19","author":"Chen","year":"2012","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.ejim.2012.10.013_bb0055","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1365-2893.2007.00957.x","article-title":"Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection","volume":"15","author":"Papatheodoridis","year":"2008","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.ejim.2012.10.013_bb0060","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.amjmed.2006.04.036","article-title":"Long-term outcome of HBV carriers with negative HBe antigen and normal aminotransferase","volume":"119","author":"Ikeda","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.ejim.2012.10.013_bb0065","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/hep.21627","article-title":"Management of hepatitis B: summary of a clinical research workshop","volume":"45","author":"Hoofnagle","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2012.10.013_bb0070","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2012.10.013_bb0075","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jhep.2007.07.022","article-title":"The clinical significance of persistently normal ALT in chronic hepatitis B infection","volume":"47","author":"Lai","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2012.10.013_bb0080","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1002\/hep.22878","article-title":"Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time","volume":"49","author":"Tai","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2012.10.013_bb0085","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2036.2010.04547.x","article-title":"Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers","volume":"33","author":"Castera","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejim.2012.10.013_bb0090","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1055\/s-2006-939751","article-title":"Hepatitis B e antigen negative chronic hepatitis B \u2014 natural history and treatment","volume":"26","author":"Hadziyannis","year":"2006","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.ejim.2012.10.013_bb0095","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1053\/jhep.2001.27834","article-title":"Hepatitis B e antigen-negative chronic hepatitis B","volume":"34","author":"Hadziyannis","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2012.10.013_bb0100","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/hep.21811","article-title":"Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B","volume":"46","author":"Feld","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2012.10.013_bb0105","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1478-3231.1999.tb00018.x","article-title":"Serum HCV RNA titer does not predict the severity of liver damage in HCV carriers with normal ALT levels","volume":"19","author":"Puoti","year":"1999","journal-title":"Liver"},{"key":"10.1016\/j.ejim.2012.10.013_bb0110","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejim.2009.12.006","article-title":"HCV carriers with normal alanine aminotransferase levels: healthy people or true patients? Dealing with an everyday clinical problem","volume":"21","author":"Puoti","year":"2010","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2012.10.013_bb0115","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.jhep.2008.06.009","article-title":"The role of serial measurement of serum HBV DNA levels in patients with chronic HBeAg-negative hepatitis B infection: association with liver disease progression. A prospective cohort study","volume":"49","author":"Zacharakis","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2012.10.013_bb0120","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2008.07.014","article-title":"Statements from the Taormina expert meeting on occult hepatitis B virus infection","volume":"49","author":"Raimondo","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2012.10.013_bb0125","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.dld.2010.10.014","article-title":"Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop","volume":"43","author":"Carosi","year":"2011","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.ejim.2012.10.013_bb0130","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2012.10.013_bb0135","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2012.10.013_bb0140","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1053\/j.gastro.2009.03.006","article-title":"Sustained response of hepatitis B e antigen-negative patients 3years after treatment with peginterferon alpha-2a","volume":"136","author":"Marcellin","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2012.10.013_bb0145","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1055\/s-2006-939758","article-title":"Antiviral drug resistance: clinical consequences and molecular aspects","volume":"26","author":"Bartholomeusz","year":"2006","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.ejim.2012.10.013_bb0150","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogues","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2012.10.013_bb0155","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/ajg.2011.45","article-title":"Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: viral suppression, viral resistance, and clinical safety","volume":"106","author":"Yuen","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejim.2012.10.013_bb0160","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2010.10.011","article-title":"Three year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B","volume":"140","author":"Heathcote","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2012.10.013_bb0165","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/gut.2005.089722","article-title":"Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B","volume":"56","author":"Bonino","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.ejim.2012.10.013_bb0170","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/hep.23722","article-title":"Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels","volume":"52","author":"Rijckborst","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2012.10.013_bb0175","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jhep.2011.12.007","article-title":"Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a","volume":"56","author":"Rijckborst","year":"2012","journal-title":"J Hepatol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620512002865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620512002865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,21]],"date-time":"2018-10-21T04:50:37Z","timestamp":1540097437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620512002865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0953620512002865"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2012.10.013","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}